Citation

Dennison E, Mohamed MA, Cooper C. Rheum. Dis. Clin. North Am. 2006; 32(4): 617-629.

Affiliation

MRC Epidemiology Resource Centre, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, United Kingdom. emd@mrc.soton.ac.uk

Copyright

(Copyright © 2006, Elsevier Publishing)

DOI

10.1016/j.rdc.2006.08.003

PMID

17288968

Abstract

Osteoporotic fractures represent a significant public health burden, which is set to increase in future generations. Lifetime risk is high and lies within the range of 40% to 50% in women and 13% to 22% in men. Life expectancy is increasing worldwide, and it is estimated that the number of individuals aged 65 years and older will increase from the current figure of 323 million to 1555 million by the year 2050. These demographic changes alone can be expected to cause the number of hip fractures occurring worldwide to increase from 1.66 million in 1990 to 6.26 million in 2050. Based on current trends, hip fracture rates might increase in the United Kingdom from 46,000 in 1985 to 117,000 in 2016. The societal cost of these fractures is high; cost-effectiveness analyses showed cost-effectiveness in treating high-risk patients with antiresorptive drugs, particularly if administered as soon as possible after a first fragility fracture.

Language: en